{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:27:45Z","timestamp":1793647665225,"version":"4.5.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Pavia","id":[{"id":"https:\/\/ror.org\/00s6t1f81","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Recent randomized trials have established that 7\u00a0days of antibiotic therapy is noninferior to 14\u00a0days for bloodstream infections (BSI) caused by susceptible organisms. Whether this conclusion extends to BSI caused by resistant pathogens is unclear. We aimed to map the available evidence on antibiotic duration for resistant BSI, by resistance category, and to identify the gaps that must be addressed before shorter courses can be recommended in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This scoping review was conducted following the Arksey and O\u2019Malley framework and reported according to PRISMA-ScR guidelines. A search of PubMed was conducted through February 2026. We included RCTs, meta-analyses, and observational studies comparing antibiotic durations for BSI. Evidence was mapped across five resistance categories: ESBL-producing Enterobacterales, carbapenemase-producing Enterobacterales (CPE), MRSA, VRE, and MDR non-fermenting Gram-negatives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 28 studies: 6 RCTs (5,182 patients, including the BALANCE pilot), 6 independent meta-analyses, 15 observational studies, and 1 post-hoc subgroup analysis of the BALANCE trial. All four definitive RCTs and all six meta-analyses confirmed noninferiority of 7-day therapy for susceptible BSI; none performed a resistance-stratified subgroup analysis for multidrug-resistant organisms (MROs). The only MRO-specific RCT (OPTIMISE, 2024) was halted after enrolling 103 of 382 planned patients. Observational data\u2014including Le Berre et al. (379 ESBL-E BSI in ICU) (Le Berre et al. in Antibiotics (Basel) 14, 2025), Soto et al. (183 CRE BSI) (Soto et al. in Clin Infect Dis 78:27\u201330, 2024), Bahrs et al. (219 VRE BSI) (Bahrs et al. in Clin Microbiol Infect 29:200\u2013207, 2023), and Gajdos et al. (EUROBACT-2, 550 hospital-acquired BSI) (Gajdos et al. in Intensive Care Med 51:518\u2013528, 2025)\u2014were consistent with no excess harm from shorter courses but were individually underpowered for noninferiority. For each of the five pre-specified resistance categories, evidence was either absent, insufficient for subgroup analysis, or derived from underpowered observational studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current RCT and meta-analytic evidence consistently supports the noninferiority of 7-day therapy for uncomplicated BSI caused by susceptible organisms. For resistant BSI, preliminary observational data are reassuring but far from definitive. Resistance-stratified trials are needed; the BALANCE\u2009+\u2009platform and SHORTEN-2 trial offer the most promising paths forward.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-026-02821-y","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:05:38Z","timestamp":1779887138000},"page":"2177-2187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Seven versus fourteen days for resistant bloodstream infections: what do we actually know? A scoping review"],"prefix":"10.1007","volume":"54","author":[{"given":"Valentina","family":"Zuccaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Asperges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea Nadia","family":"Marvulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Valsecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Sacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"6","key":"2821_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/cc10545","volume":"15","author":"TC Havey","year":"2011","unstructured":"Havey TC, Fowler RA, Daneman N. Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis. Crit Care. 2011;15(6):R267. https:\/\/doi.org\/10.1186\/cc10545.","journal-title":"Crit Care"},{"issue":"7","key":"2821_CR2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/cid\/ciy1054","volume":"69","author":"D Yahav","year":"2019","unstructured":"Yahav D, Franceschini E, Koppel F, et al. Seven versus 14 days of antibiotic therapy for uncomplicated Gram-negative bacteremia: a noninferiority randomized controlled trial. Clin Infect Dis. 2019;69(7):1091\u20138. https:\/\/doi.org\/10.1093\/cid\/ciy1054.","journal-title":"Clin Infect Dis"},{"issue":"21","key":"2821_CR3","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1001\/jama.2020.6348","volume":"323","author":"E von Dach","year":"2020","unstructured":"von Dach E, Albrich WC, Brunel AS, et al. C-reactive protein-guided antibiotic treatment duration for uncomplicated Gram-negative bacteremia. JAMA. 2020;323(21):2160\u20139. https:\/\/doi.org\/10.1001\/jama.2020.6348.","journal-title":"JAMA"},{"issue":"4","key":"2821_CR4","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cmi.2021.09.001","volume":"28","author":"J Molina","year":"2022","unstructured":"Molina J, Montero-Mateos E, Praena-Segovia J, et al. Seven- versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial. Clin Microbiol Infect. 2022;28(4):550\u20137. https:\/\/doi.org\/10.1016\/j.cmi.2021.09.001.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"2821_CR5","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1056\/NEJMoa2404991","volume":"392","author":"BALANCE Investigators","year":"2025","unstructured":"BALANCE Investigators. Antibiotic treatment for 7 versus 14 days in patients with bloodstream infections. N Engl J Med. 2025;392(11):1065\u201378. https:\/\/doi.org\/10.1056\/NEJMoa2404991.","journal-title":"N Engl J Med"},{"issue":"3","key":"2821_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.1421","volume":"8","author":"TC Lee","year":"2025","unstructured":"Lee TC, Prosty CJ, Fralick M, et al. Seven vs fourteen days of antibiotics for Gram-negative BSI: a systematic review and noninferiority meta-analysis. JAMA Netw Open. 2025;8(3):e251421. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.1421.","journal-title":"JAMA Netw Open"},{"key":"2821_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40121-025-01258-4","volume":"15","author":"G Luna","year":"2026","unstructured":"Luna G, Rodriguez A, Igbonagwam C, et al. Seven versus fourteen days of antibiotics for Gram-negative bacteremia from a urinary tract source: a systematic review and meta-analysis. Infect Dis Ther. 2026;15:491\u2013505. https:\/\/doi.org\/10.1007\/s40121-025-01258-4.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"2821_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-024-05178-6","volume":"28","author":"B Arns","year":"2024","unstructured":"Arns B, Kalil AC, Sorio GGL, et al. Seven versus 14 days of antimicrobial therapy for severe multidrug-resistant Gram-negative bacterial infections in intensive care unit patients (OPTIMISE): a randomised, open-label, non-inferiority clinical trial. Crit Care. 2024;28(1):412. https:\/\/doi.org\/10.1186\/s13054-024-05178-6.","journal-title":"Crit Care"},{"issue":"5","key":"2821_CR9","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s10096-019-03491-z","volume":"38","author":"A Sousa","year":"2019","unstructured":"Sousa A, P\u00e9rez-Rodr\u00edguez MT, Su\u00e1rez M, et al. Short- versus long-course therapy in Gram-negative bacilli bloodstream infections. Eur J Clin Microbiol Infect Dis. 2019;38(5):851\u20137. https:\/\/doi.org\/10.1007\/s10096-019-03491-z.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"9","key":"2821_CR10","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1093\/cid\/ciad009","volume":"76","author":"J McAteer","year":"2023","unstructured":"McAteer J, Lee JH, Cosgrove SE, et al. Defining the optimal duration of therapy for hospitalized patients with complicated urinary tract infections and associated bacteremia. Clin Infect Dis. 2023;76(9):1604\u201312. https:\/\/doi.org\/10.1093\/cid\/ciad009.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2821_CR11","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.cmi.2018.01.021","volume":"24","author":"M Giannella","year":"2018","unstructured":"Giannella M, Pascale R, Toschi A, et al. Treatment duration for Escherichia coli bloodstream infection and outcomes: retrospective single-centre study. Clin Microbiol Infect. 2018;24(10):1077\u201383. https:\/\/doi.org\/10.1016\/j.cmi.2018.01.021.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"2821_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14040358","volume":"14","author":"C Le Berre","year":"2025","unstructured":"Le Berre C, Degrendel M, Houard M, et al. Optimizing antibiotic treatment duration for ESBL-producing Enterobacteriaceae bacteremia in ICU: a multicentric retrospective cohort study. Antibiotics (Basel). 2025;14(4):358. https:\/\/doi.org\/10.3390\/antibiotics14040358.","journal-title":"Antibiotics (Basel)"},{"issue":"1","key":"2821_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/cid\/ciad476","volume":"78","author":"CL Soto","year":"2024","unstructured":"Soto CL, Hsu AJ, Lee JH, et al. Identifying effective durations of antibiotic therapy for the treatment of carbapenem-resistant Enterobacterales bloodstream infections: a multicenter observational study. Clin Infect Dis. 2024;78(1):27\u201330. https:\/\/doi.org\/10.1093\/cid\/ciad476.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2821_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19\u201332. https:\/\/doi.org\/10.1080\/1364557032000119616.","journal-title":"Int J Soc Res Methodol"},{"key":"2821_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-5-69","volume":"5","author":"D Levac","year":"2010","unstructured":"Levac D, Colquhoun H, O\u2019Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5:69. https:\/\/doi.org\/10.1186\/1748-5908-5-69.","journal-title":"Implement Sci"},{"issue":"7","key":"2821_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373. https:\/\/doi.org\/10.7326\/M18-0850.","journal-title":"Ann Intern Med"},{"issue":"1","key":"2821_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12874-018-0611-x","volume":"18","author":"Z Munn","year":"2018","unstructured":"Munn Z, Peters MDJ, Stern C, et al. Systematic review or scoping review? BMC Med Res Methodol. 2018;18(1):143. https:\/\/doi.org\/10.1186\/s12874-018-0611-x.","journal-title":"BMC Med Res Methodol"},{"key":"2821_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103195","volume":"83","author":"SWX Ong","year":"2025","unstructured":"Ong SWX, Pinto R, Rishu A, et al. Identifying heterogeneity of treatment effect for antibiotic duration in bloodstream infection: an exploratory post-hoc analysis of the BALANCE randomised clinical trial. eClinicalMedicine. 2025;83:103195. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103195.","journal-title":"eClinicalMedicine"},{"issue":"5","key":"2821_CR19","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s15010-017-1020-5","volume":"45","author":"AN Nelson","year":"2017","unstructured":"Nelson AN, Justo JA, Bookstaver PB, et al. Optimal duration of antimicrobial therapy for uncomplicated Gram-negative bloodstream infections. Infection. 2017;45(5):613\u201320. https:\/\/doi.org\/10.1007\/s15010-017-1020-5.","journal-title":"Infection"},{"issue":"2","key":"2821_CR20","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/cid\/cix767","volume":"66","author":"D Chotiprasitsakul","year":"2018","unstructured":"Chotiprasitsakul D, Han JH, Cosgrove SE, et al. Comparing the outcomes of adults with Enterobacteriaceae bacteremia receiving short-course versus prolonged-course antibiotic therapy in a multicenter, propensity score-matched cohort. Clin Infect Dis. 2018;66(2):172\u20137. https:\/\/doi.org\/10.1093\/cid\/cix767.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2821_CR21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/cid\/ciad670","volume":"78","author":"S Tingsg\u00e5rd","year":"2024","unstructured":"Tingsg\u00e5rd S, Bastrup Israelsen S, \u00d8stergaard C, Benfield T. Emulating a target trial of shorter compared to longer course of antibiotic therapy for Gram-negative bacteremia. Clin Infect Dis. 2024;78(2):292\u2013300. https:\/\/doi.org\/10.1093\/cid\/ciad670.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2821_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.52314","volume":"7","author":"S Tingsg\u00e5rd","year":"2024","unstructured":"Tingsg\u00e5rd S, Bastrup Israelsen S, J\u00f8rgensen HL, et al. Early switch from intravenous to oral antibiotics for patients with uncomplicated Gram-negative bacteremia. JAMA Netw Open. 2024;7(1):e2352314. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.52314.","journal-title":"JAMA Netw Open"},{"key":"2821_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2022.154257","volume":"74","author":"P Zuercher","year":"2023","unstructured":"Zuercher P, Moser A, Frey MC, et al. Duration of antimicrobial treatment for bacteremia in critically ill patients. J Crit Care. 2023;74:154257. https:\/\/doi.org\/10.1016\/j.jcrc.2022.154257.","journal-title":"J Crit Care"},{"issue":"3","key":"2821_CR24","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00134-025-07857-6","volume":"51","author":"L Gajdos","year":"2025","unstructured":"Gajdos L, Buetti N, Tabah A, et al. Shortening antibiotic therapy duration for hospital-acquired bloodstream infections in critically ill patients: a causal inference model from the international EUROBACT-2 database. Intensive Care Med. 2025;51(3):518\u201328. https:\/\/doi.org\/10.1007\/s00134-025-07857-6.","journal-title":"Intensive Care Med"},{"issue":"2","key":"2821_CR25","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.cmi.2022.08.027","volume":"29","author":"C Bahrs","year":"2023","unstructured":"Bahrs C, Rieg S, Hennigs A, et al. Short-course versus long-course antibiotic treatment for uncomplicated vancomycin-resistant enterococcal bacteraemia: a retrospective multicentre cohort study. Clin Microbiol Infect. 2023;29(2):200\u20137. https:\/\/doi.org\/10.1016\/j.cmi.2022.08.027.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"2821_CR26","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.cmi.2019.10.008","volume":"26","author":"M Abbas","year":"2020","unstructured":"Abbas M, Rossel A, de Kraker MEA, et al. Association between treatment duration and mortality or relapse in adult patients with Staphylococcus aureus bacteraemia: a retrospective cohort study. Clin Microbiol Infect. 2020;26(5):626\u201331. https:\/\/doi.org\/10.1016\/j.cmi.2019.10.008.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"2821_CR27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/jac\/dkac394","volume":"78","author":"RN Evans","year":"2023","unstructured":"Evans RN, Harris J, Rogers CA, Macgowan AP. The effect of duration of therapy for treatment of Staphylococcus aureus blood stream infection: an application of cloning to deal with immortal-time bias. J Antimicrob Chemother. 2023;78(1):196\u2013204. https:\/\/doi.org\/10.1093\/jac\/dkac394.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2821_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13063-018-2483-4","volume":"19","author":"N Daneman","year":"2018","unstructured":"Daneman N, Rishu AH, Pinto R, et al. 7 versus 14 days of antibiotic treatment for critically ill patients with bloodstream infection: a pilot randomized clinical trial. Trials. 2018;19(1):111. https:\/\/doi.org\/10.1186\/s13063-018-2483-4.","journal-title":"Trials"},{"key":"2821_CR29","doi-asserted-by":"publisher","unstructured":"Tamma PD, Heil EL, Justo JA, et al. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis. 2024;ciae403. https:\/\/doi.org\/10.1093\/cid\/ciae403.","DOI":"10.1093\/cid\/ciae403"},{"issue":"1","key":"2821_CR30","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s13063-019-3324-0","volume":"20","author":"L Thorlacius-Ussing","year":"2019","unstructured":"Thorlacius-Ussing L, Petersen E, Andersen CO, et al. SAB7: Staphylococcus aureus bacteremia treated for 7 versus 14 days: a protocol for a randomized controlled trial. Trials. 2019;20(1):250. https:\/\/doi.org\/10.1186\/s13063-019-3324-0.","journal-title":"Trials"},{"key":"2821_CR31","doi-asserted-by":"publisher","DOI":"10.1177\/87551225251396748","author":"E Torres","year":"2025","unstructured":"Torres E, Hlavacek NL, Cabanilla MG. Short-course therapy for uncomplicated VRE bacteremia: this is us trying (to shorten therapy). Ann Pharmacother. 2025. https:\/\/doi.org\/10.1177\/87551225251396748.","journal-title":"Ann Pharmacother"},{"issue":"12","key":"2821_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277333","volume":"17","author":"J Molina","year":"2022","unstructured":"Molina J, Rosso-Fern\u00e1ndez CM, Montero-Mateos E, et al. Study protocol for a randomized clinical trial to assess 7 versus 14 days of treatment for Pseudomonas aeruginosa bloodstream infections (SHORTEN-2 trial). PLoS ONE. 2022;17(12):e0277333. https:\/\/doi.org\/10.1371\/journal.pone.0277333.","journal-title":"PLoS ONE"},{"issue":"10","key":"2821_CR33","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/jama.2018.12163","volume":"320","author":"PNA Harris","year":"2018","unstructured":"Harris PNA, Tambyah PA, Lye DC, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with Escherichia coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA. 2018;320(10):984\u201394. https:\/\/doi.org\/10.1001\/jama.2018.12163.","journal-title":"JAMA"},{"issue":"12","key":"2821_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2025-101588","volume":"15","author":"N Daneman","year":"2025","unstructured":"Daneman N, Johnstone J, MacFadden DR, et al. Assessing the feasibility of a platform trial for Gram negative bloodstream infections: results from the vanguard phase of BALANCE+. BMJ Open. 2025;15(12):e101588. https:\/\/doi.org\/10.1136\/bmjopen-2025-101588.","journal-title":"BMJ Open"},{"key":"2821_CR35","doi-asserted-by":"publisher","first-page":"1617328","DOI":"10.3389\/fmed.2025.1617328","volume":"12","author":"C Zhao","year":"2025","unstructured":"Zhao C, Chen C, Lu D, et al. Antibiotic treatment for 7 days versus 14 days in patients with uncomplicated bloodstream infections: a systematic review, meta-analysis, and trial sequential analysis. Front Med. 2025;12:1617328. https:\/\/doi.org\/10.3389\/fmed.2025.1617328.","journal-title":"Front Med"},{"issue":"5","key":"2821_CR36","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s15010-025-02562-4","volume":"53","author":"M Prager","year":"2025","unstructured":"Prager M, Bergmann F, Pracher L, et al. Antimicrobial treatment for 7 versus 14 days in patients with bacteremia: a meta-analysis of randomized controlled trials. Infection. 2025;53(5):2159\u201368. https:\/\/doi.org\/10.1007\/s15010-025-02562-4.","journal-title":"Infection"},{"key":"2821_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103397","volume":"86","author":"M Liu","year":"2025","unstructured":"Liu M, Gao Y, Zheng L, et al. Shorter versus longer-duration antibiotic treatments for immunocompetent patients with bloodstream infections: a systematic review and meta-analysis. eClinicalMedicine. 2025;86:103397. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103397.","journal-title":"eClinicalMedicine"},{"key":"2821_CR38","doi-asserted-by":"publisher","unstructured":"Turjeman A, von Dach E, Molina J, et al. Duration of antibiotic treatment for Gram-negative bacteremia: systematic review and individual participant data (IPD) meta-analysis. eClinicalMedicine. 2022;55:101750. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101750.","DOI":"10.1016\/j.eclinm.2022.101750"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02821-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02821-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02821-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:49:23Z","timestamp":1793645363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02821-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2821"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02821-y","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"14 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This scoping review is based exclusively on published data from peer-reviewed studies. No ethical approval was required.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The lead author affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.","order":3,"name":"Ethics","label":"Transparency declaration","group":{"name":"EthicsHeading","label":"Declarations"}}]}}